Objective: After cancer treatment, troublesome menopausal symptoms are common but poorly understood. Using standardized instruments, we measured differences in symptom nature, severity, impact on quality of life, and sexual function between cancer survivors and noncancer participants.
M ore than 151,000 women in Australia (nearly 4% of the female population) are cancer survivors 1 (more than 15 million worldwide 2 ). More than a third of those are breast cancer survivors. 1 In developed countries, cancer survival rates, particularly of breast cancer, have rapidly risen in the past 30 years, 1,3 emphasizing the importance of survivorship issues. 4 Menopausal symptoms are a frequent and distressing effect of cancer treatments in women. 5, 6 Ovarian tissue is highly sensitive to the radiation or cytotoxic regimens commonly used in breast, colorectal, gynecologic, and hematologic cancers. 7<10 In hormone-sensitive breast and gynecologic cancers, suppression of estrogen production or action improves cancer outcomes. 11 Several small observational studies 12<16 have suggested that menopausal symptoms in cancer survivors may differ in nature and severity from those seen in noncancer participants. However, no previous studies have compared a large population of cancer survivors with menopausal symptoms with noncancer participants presenting for treatment of menopausal symptoms to determine differences in nature, severity, impact on quality of life, and sexual function using standardized and validated instruments. The aim of this study was to describe how menopausal symptoms differ in these key areas between cancer survivors and noncancer participants. Further information about nature, severity, and impact on quality of life is needed to develop appropriate services and therapeutic options for the growing population of female cancer survivors.
METHODS
Between January 2003 and November 2010, we collected data on all first visits to a multidisciplinary Menopause Symptoms After Cancer (MSAC) Clinic and, when funding became available in 2008, to the Menopause Clinic of the King Edward Memorial Hospital, a public tertiary women's hospital that serves a population of around 1.3 million women in Western Australia. Data on marital status, occupation, smoking status, alcohol intake, family cancer history, parity, gravidity, menopause status, and date of last menstrual period were collected. Women were considered premenopausal if they had regular menstrual periods and no vasomotor symptoms; perimenopausal if they had changes in menstrual cycle and/or new-onset vasomotor symptoms; and postmenopausal if they were more than 1 year past their last menstrual period. 17 Gynecologic history, history of previous hormone therapy (HT) and non-HT for menopausal symptoms, and history of hypertension, diabetes, venous thrombotic event, anxiety, and depression were recorded at the first visit. Information about the nature, stage, and grade of cancer plus cancer therapy was collected from medical records. Where possible, the nature of menopause (spontaneous, surgical, chemotherapy-induced, or radiationinduced) was identified from clinical history and discussion with women.
All women attending the MSAC Clinic were invited to participate. The study was approved by the institutional ethics committee at King Edward Memorial Hospital in Western Australia.
Questionnaires
Participants were asked to report their symptoms currently, within the previous week, and within the previous month. Current menopausal symptoms were collected using the Greene Climacteric Scale, 18 a validated self-report questionnaire for which age-specific Australian population norms have been published. 19 Past-week symptoms were evaluated using the Functional Assessment of Cancer Therapy (FACT) family of instruments 20 (www.facit.org). Participants completed the 19-item endocrine symptom subscale 21 and selected items from the FACT general scale 20 and breast cancer subscale (version 4). These tools are appropriate for use in women with and without cancer. 20, 22, 23 Some items were not administered because they are not appropriate for women without cancer (eg, BI am losing hope in the fight against my illness[). Global well-being scores were derived from these instruments. 24 Sexual function during the previous month was reported using Fallowfield's Sexual Activity Questionnaire (SAQ), 25 which has been validated in populations of women with and without cancer, as well as in high-risk women. 26 Detailed information on participant completion of the components of all scale components, as well as examples of scale items, may be found in Table, Supplemental Digital Content 1, http://links.lww.com/MENO/A57.
Vasomotor symptoms
In addition to the Greene Climacteric Scale assessment of current hot flushes and night sweats, participants were asked to report the number of hot flushes of each of four severities (Bmild,[ Bmoderate,[ Bsevere,[ Bvery severe[) they had experienced in the previous 24 hours. The endocrine symptom subscale vasomotor symptom assessment evaluates the pastweek impact of hot flushes, night sweats, cold sweats, and sleep disruption.
Neuropsychological symptoms
The Greene Climacteric Scale psychological domain includes anxiety and depression subscales. Women were also assessed with neuropsychological items from the FACT scale and completed the social/family well-being subscale.
Somatic symptoms
The Greene Climacteric Scale asks participants to describe the extent to which they are troubled by seven items in the somatic domain. We also asked items from the FACT endocrine symptoms subscale pertaining to gastrointestinal function in the past week and from the physical well-being subscale or the functional well-being subscale.
Gynecologic symptoms and sexual function
The Greene Climacteric Scale assesses the current extent to which participants are troubled by Bloss of interest in sex. [ 25 All participants completed the first section of the instrument, which investigates current sexual activity status. Section II, completed by sexually inactive women, lists reasons for the lack of sexual activity. Section III, completed by sexually active women, consists of 10 Likert-format items on sexual feelings and experiences in the previous months, in the pleasure scale (SAQ-P), discomfort scale (SAQ-D), and habit scale (SAQ-H).
Statistical analyses
For demographic and lifestyle characteristics, betweengroup comparisons of median values for continuous variables were conducted using Fisher's exact test for equality of medians, and between-group comparisons of the distribution of categorical variables were conducted using two-sided Fisher's exact tests.
Analyses of the Greene Climacteric Scale were limited to women for whom data were complete for at least one domain. Scoring within domains was skewed for the Greene Climacteric Scale and SAQ; thus, medians and ranges were reported to describe score distributions, and nonparametric tests were used to compare scores between groups. For the Greene Climacteric Scale domains (with the exception of the sexual interest item), we reported the proportion of study groups scoring above the upper bound of published 95% reference ranges 19 for postmenopausal women (who score higher on most Greene Climacteric Scale domains than premenopausal or perimenopausal women). Mean scores for the FACT social/ family well-being, functional well-being, and physical wellbeing subscales were compared using t tests for unequal variances. Binary variables were derived from the Greene Climacteric Scale domains by grouping women who were troubled Bquite a bit[ or Bextremely[ for half the scale items or more within that domain. Similarly, women who had reported Ba little[ or Bnot at all[ for three or more of the six items on SAQ-P were classified as having low sexual pleasure, and those who had reported Bvery much[ feeling pain or discomfort during penetration or dryness of the vagina were classified as having high sexual discomfort. Those who reported Bquite a bit[ or Bvery much[ for symptoms derived from the FACT scales were classified as having severe symptomsVexcept for the item BI am sleeping well,[ which was classified as severe if participants endorsed Bnot at all[ or Ba little bit.[ Relationships between binary variables and cancer status were explored using logistic regression analysis, adjusted for age at visit, age at menopause, current use of HT, and current use of endocrine therapy.
Data analysis was conducted using Stata statistical software version 11.2 (release 11, 2009; StataCorp LP, College Station, TX). All hypothesis tests were two-sided, and P G 0.05 was considered statistically significant.
RESULTS

Study group characteristics
Demographic and lifestyle characteristics of the study groups (934 cancer survivors and 155 noncancer participants) are shown in Table 1 . For both groups, the median age at first clinic visit was 51 years, and the median age at menopause was 46 years. Noncancer participants were more likely to have experienced natural menopause (59% vs 33%). Noncancer participants were more likely to have experienced surgical menopause compared with cancer survivors (41% vs 26%). Most participants were married or in de facto relationships and had given birth to at least one child. There were no significant differences in smoking or alcohol use. Lifetime HT use and current HT use were more common in noncancer participants than in cancer survivors (ever HT: 38% of cancer survivors vs 50% of noncancer participants; current HT: 5% vs 13.5%). Lifetime use of clonidine was higher among cancer survivors than among noncancer participants (5.8% vs 1.3%), but use of selective serotonin-norepinephrine reuptake inhibitors and gabapentin did not differ. Use of complementary/alternative therapies was more common among cancer survivors than among noncancer participants (17.5% vs 7.1%).
The characteristics of cancer survivors are presented in Table 2 . More than half of the cancer survivors referred to the MSAC Clinic for management of menopausal symptoms were perimenopausal or postmenopausal when their cancer was diagnosed. More than half of the survivors had undergone treatment more than a year before their clinic visit, and 13% had been treated 5 years or more previously. The great majority of survivors had a previous diagnosis of breast cancer (82%). A smaller proportion had had a gynecologic cancer (10.5%), with the remainder (7.5%) having had hematologic and colorectal malignancies. A small percentage (5%) had more than one previous cancer.
All participants were offered all instruments. Ninety percent (n = 841) of cancer survivors and 98.7% (n = 153) of noncancer participants completed at least part of the 
Vasomotor symptoms
Seventy-nine percent of cancer survivors and 61% of noncancer participants reported current severe vasomotor symptoms (Table 3) . Thirty-six percent of cancer survivors and 23% of noncancer participants scored in excess of the upper bound of the published reference range for vasomotor symptoms (Table, Supplemental Digital Content 2, http://links.lww.com/MENO/A58). Current severe trouble with vasomotor symptoms was more probable among cancer survivors after accounting for age at visit, age at menopause, and current HT (P = 0.027; Table 3 ). The difference between groups was attributable to a greater likelihood of severe trouble with hot flushes (P = 0.022).
In the past 24 hours, cancer survivors were more likely than noncancer participants to report hot flushes (P G 0.001). Cancer survivors were more likely than noncancer participants to report severe or very severe flushes (P = 0.008) in the last 14 hours, after adjusting for the same factors. Cancer survivors also reported more frequent flushes than noncancer participants (cancer survivors: mean, 6.0; 95% CI, 5.6-6.4; noncancer participants: mean, 3.1; 95% CI, 2.4-3.8; t test; P G 0.001) and were substantially more likely than noncancer participants to report 10 or more hot flushes in the previous 24 hours (P = 0.004; Table 3 ). psychological symptoms. This difference between groups was attributable to differences in the depression subscore of the Greene Climacteric Scale ( In the past week, cancer survivors were less likely than noncancer participants to have severe mood swings (P = 0.004), irritability (P = 0.003), or sadness (P = 0.024; Table 4 ). Cancer survivors also scored significantly better in social/family well-being than noncancer participants (P = 0.002; Table 4 ).
Somatic symptoms
Somatic symptoms were less troublesome for cancer survivors than for noncancer participants (P G 0.001)Va difference consistent across all items, except for breathing difficulties and muscle/joint pains ( Table 5 ). Twelve percent of cancer survivors and 24% of noncancer participants scored in excess of the upper bound of the published reference range for somatic symptoms (Table, Supplemental Digital Content 1, http://links.lww.com/MENO/A57). Cancer survivors were less likely than noncancer participants to report severe headaches (P = 0.04), weight gain (P = 0.01), or bloating (P = 0.02) in the previous week (Table 5 ). Mean physical well-being scores and functional well-being scores did not differ between cancer and noncancer participants.
Gynecologic symptoms and sexual function
Although 79% of all participants were currently in a relationship, only 59% were sexually active. Overall, no significant differences in sexual activity or function were observed between cancer and noncancer participants. However, cancer survivors were significantly more likely than noncancer participants to attribute their sexual inactivity to a Bphysical problem that makes sexual relations difficult or uncomfortable[ (21% vs 3%, P = 0.013; Table 6 ).
Thirty-seven percent of cancer survivors and 34% of noncancer participants scored in excess of the upper bound of the published reference range for loss of interest in sexual activity (Table, Supplemental Digital Content 1, http://links.lww.com/MENO/A57), but this should be interpreted cautiously as the range for this domain of the Greene Climacteric Scale is very small (0-3) and, thus, score variability is limited.
Severe vaginal dryness troubled 49% of this study population but did not differ significantly between cancer and noncancer populations. Severe loss of sexual interest was also common (troubling 65% of participants and affecting 45% within the past week) but did not differ by cancer status.
DISCUSSION
This is the first large clinic-based study to measure the nature, severity, and impact of menopausal symptoms on sexual function and quality of life in cancer survivors compared with noncancer participants. After accounting for age and use of menopausal HT, we found hot flushes to be strikingly more troublesome, severe, and frequent among cancer survivors than among noncancer participants, consistent with previous smaller studies. 12, 27 It is notable that many cancer survivors presented with menopausal symptoms many years since their original diagnosis, indicating the persistence and prevalence of menopausal symptoms in this population. Although HT use at the first clinic visit was more than twice as frequent in noncancer participants as in cancer survivors (13.5% vs 5%), HT use was uncommon and did not account for differences in multivariate analysis. Although lifetime clonidine use was more common among cancer survivors, indication information was not available, and lifetime use of other nonhormonal medications for vasomotor symptoms did not differ between groups. Complementary and alternative therapies, including use of herbal preparations, were more common among cancer survivors. However, this finding should be taken cautiously because, if survivors are more Denominator refers to women within the category reporting any hot flushes in the past 24 hours. focused on maintaining health, they might be more likely to recall and report these and other therapies than other women. Data on body mass index, which could potentially have impacted on vasomotor symptoms, were not available.
The observation that psychological symptoms, particularly depressive symptoms, were more prevalent in noncancer participants than in cancer survivors was unexpected. More than a quarter of noncancer participants scored above the reference range for psychological symptoms. 19 However, this observation is consistent with recent reports indicating that more than one third of gynecologic outpatients meet diagnostic criteria for an anxiety or depressive disorder. 28 The reason for this difference in emotional well-being is not known but may be attributable to the better social and psychological support associated with a cancer diagnosis compared with that of menopause. 20 This is the first time that psychological symptoms have been compared between these groups using validated instruments. A small study in Brazil, using a nonstandardized measurement tool, reported no differences in Bnervousness, headache, depression, and insomnia[ between cancer survivors and controls with menopausal symptoms. 13 We used a validated menopause scale with a psychological symptoms domain (Greene Climacteric Scale), rather than a mental health tool, to measure psychological symptoms. Further comparative studies using validated measurement scales for anxiety and depression are needed. Both cancer and noncancer survivors had considerably more severe psychological symptoms than published norms, 19 although the 20% to 25% prevalence of severe trouble with menopausal symptoms in these mental health domains in cancer survivors is consistent with previous studies of menopausal breast cancer survivors. 29, 30 We were surprised to find that cancer survivors were less likely to report psychological symptoms. Psychological support through hospital services and consumer organizations is available for cancer survivors in Australia, particularly breast cancer survivors. It is possible that cancer survivors referred to the MSAC Clinic had already received psychological support, which may explain the lower reports of psychological symptoms in this population. Also, many survivors were some years past their cancer diagnosis. Psychological morbidity is common upon diagnosis of breast and gynecologic cancers, but symptoms improve significantly over time, 31 and the early psychological symptoms associated with a cancer diagnosis may have resolved. Also, it is well recognized that symptoms of anxiety and depression are common in women at menopause. 32, 33 Furthermore, those women attending a gynecology outpatient clinic may be more likely to report psychological symptoms than women in the general community. 34 Somatic symptoms measured by the Greene Climacteric Scale (eg, Bpressure or tightness in head or body[ and Bheadaches[) were also more common in noncancer participants, as were some of the somatic symptoms measured by the FACT breast cancer subscale (eg, Bweight gain[ and Bbloating[). These somatic symptoms are not specific, not clearly attributable to endocrine changes at menopause, 35 and may further reflect the worse psychological condition of noncancer participants undergoing menopause.
We were surprised to find that sexual dysfunction symptoms did not differ by cancer status, but severe vaginal dryness, pain during sexual intercourse, and loss of interest in sex were very common and troublesome in both groups. This contrasts with the few studies comparing women with a breast cancer history 12, 36, 37 or cervical cancer, 16, 38, 39 which found worse gynecologic and sexual functions, but most of these studies did not account for menopause status. 36<39 A relatively high proportion of noncancer participants (41%) had gone through surgical menopause. It is well recognized that surgical menopause may be more likely than natural menopause to lead to sexual dysfunction, 40 and this may have contributed to our observations. Compared with noncancer participants, cancer survivors were more likely to attribute their sexual inactivity to a Bphysical problem that makes sexual relations difficult or uncomfortable.[ This does not seem to reflect increased levels of vaginal dryness in cancer participants, as this was common in both groups. Further qualitative studies may shed further light on the physical problems that negatively impacted on sexual function in these cancer participants.
The current study has certain limitations. This was a convenience sample, and the cancer participants are skewed toward the most common types of cancer in women. Because close to 90% of the survivors had a history of breast cancer, our findings mainly reflect this population. Ethnicity data are not available for individual participants, but the hospital serves a population that is 90% white. Menopausal symptoms are known to differ in nature and severity according to ethnicity, 41 but our ethnically homogenous sample minimizes these variations. 0.55 Odds ratios adjusted for age at menopause, age at visit, and current use of hormone therapy, except where otherwise noted. Boldface indicates statistically significant relationship (P G 0.05).
